{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T12:32:06Z","timestamp":1781353926726,"version":"3.54.1"},"reference-count":30,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2006,9,14]],"date-time":"2006-09-14T00:00:00Z","timestamp":1158192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Chemotherapy\u2010related anemia is prevalent among patients with hematologic malignancies. A randomized, open\u2010label, multicenter trial of early versus late epoetin alfa in this population was conducted, focusing on quality of life (QOL).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with non\u2010Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia, or multiple myeloma and baseline hemoglobin of 10 to 12 g\/dL who were scheduled for \u22654 months of myelosuppressive chemotherapy were randomized to receive \u226416 weeks of epoetin alfa at a dose of 40,000 U once weekly immediately (early) or to wait and only receive epoetin alfa if hemoglobin decreased to &lt;9 g\/dL (late). Those patients with a hemoglobin level &gt;12 g\/dL after 3 chemotherapy cycles were not randomized. The primary endpoint was a mean change in the Functional Assessment of Cancer Therapy\u2010Anemia (FACT\u2010An) total.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>In all, 269 patients with a hemoglobin level \u226412 g\/dL were randomized. The mean total FACT\u2010An increased 3.84 (95% confidence interval [95% CI], 0.21\u20137.46) in early patients and decreased 4.37 (95% CI, \u22127.99 to \u22120.74) in late patients (<jats:italic>P<\/jats:italic> = .003). Early patients had significantly (<jats:italic>P<\/jats:italic> &lt; .05) higher mean scores for total FACT\u2010General; FACT\u2010General physical and functional well\u2010being subscales, total anemia scale, and fatigue subscale; and daily activity, energy, and important activity Linear Analog Scale Assessment scales, as well as reduced bedrest days and restricted activity days. The mean hemoglobin increased 1.2 g\/dL (95% CI, 0.98\u20131.46) in early patients but decreased 0.2 g\/dL (95% CI, \u22120.32\u20130.12) in late patients (<jats:italic>P<\/jats:italic> &lt; .0001). Adverse events were similar between groups (with fatigue being the most prevalent); clinically relevant thromboembolic events were more common in early patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Treating mild anemia immediately with epoetin alfa during chemotherapy for hematologic malignancy significantly improved QOL, productivity, and hemoglobin compared with delaying treatment until the hemoglobin level decreases to &lt;9.0 g\/dL. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22221","type":"journal-article","created":{"date-parts":[[2006,9,14]],"date-time":"2006-09-14T21:23:56Z","timestamp":1158269036000},"page":"1909-1917","source":"Crossref","is-referenced-by-count":52,"title":["Quality\u2010of\u2010life and health benefits of early treatment of mild anemia"],"prefix":"10.1002","volume":"107","author":[{"given":"David J.","family":"Straus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia A.","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda J.","family":"Sarokhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Tulpule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph R.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley A.","family":"Riggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.06.019"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf122"},{"issue":"7","key":"e_1_2_6_4_2","first-page":"43","article-title":"Factors influencing quality of life in cancer patients: anemia and fatigue","volume":"25","author":"Cella D","year":"1998","journal-title":"Semin Oncol."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.5-5-353"},{"issue":"2","key":"e_1_2_6_6_2","first-page":"4","article-title":"Patient, caregiver, and oncologist perceptions of cancer\u2010related fatigue: results of a tripart assessment survey","volume":"34","author":"Vogelzang NJ","year":"1997","journal-title":"Semin Hematol."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600247"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10763"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2004.0040"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.16.1204"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.177"},{"key":"e_1_2_6_12_2","volume-title":"Cancer and treatment\u2010related anemia. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology v. 2","author":"Rodgers GM","year":"2006"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02715.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2875"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04439.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.16.1211"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00274-6"},{"key":"e_1_2_6_19_2","volume-title":"Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System.","author":"Cella D","year":"1997"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.17.1490"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0885-3924(02)00529-8","article-title":"Combining anchor and distribution\u2010based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales","volume":"24","author":"Cella D","year":"2002","journal-title":"J Pain Symptom Manage."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00628-7"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"609a","DOI":"10.1182\/blood.V104.11.2217.2217","article-title":"Cognitive effects of once weekly (QW) epoetin alfa in anemic patients (pts) with hematologic malignancies receiving chemotherapy (CT): interim results of the EPOLYM trial","volume":"104","author":"Gisselbrecht C","year":"2004","journal-title":"Blood"},{"key":"e_1_2_6_24_2","first-page":"36","article-title":"Quality\u2010of\u2010life assessment in diabetes research: interpreting the magnitude and meaning of treatment effects","volume":"13","author":"Testa MA","year":"2000","journal-title":"Diabetes Spect."},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"II\u2013166","DOI":"10.1097\/00005650-200009002-00026","article-title":"Interpretation of quality of life outcomes: issues that affect magnitude and meaning","volume":"38","author":"Testa MA","year":"2000","journal-title":"Med Care"},{"issue":"1","key":"e_1_2_6_26_2","first-page":"S9","article-title":"Interpreting quality of life clinical trial data for use in the clinical practice of antihypertensive therapy","volume":"5","author":"Testa MA","year":"1987","journal-title":"J Hypertens"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14567-9"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.150"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji087"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj189"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/oso\/9780198528470.003.0006","volume-title":"Biases in responding. Health Measurement Scales: A Practical Guide to Their Development and Use.","author":"Streiner DL","year":"2003"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22221","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:51:49Z","timestamp":1760273509000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22221"}},"subtitle":["A randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies"],"short-title":[],"issued":{"date-parts":[[2006,10,3]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,10,15]]}},"alternative-id":["10.1002\/cncr.22221"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22221","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,3]]}}}